scholarly journals Effect of the TNFα-308 G/A Polymorphism on the Changes Produced by Atorvastatin in Bone Mineral Density in Patients with Acute Coronary Syndrome

2008 ◽  
Vol 53 (2) ◽  
pp. 117-121 ◽  
Author(s):  
José Luis Pérez-Castrillón ◽  
Gemma Vega ◽  
Laura Abad ◽  
Alberto Sanz-Cantalapiedra ◽  
Manuel Gonzalez Sagredo ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Acute Coronary Syndrome ◽  
Bone Mineral ◽  
Tnf Alpha ◽  
Mineral Density ◽  
Coronary Syndrome

Lipids and Bone Mineral Density in Patients with Vascular Disease

2008 ◽  
Vol 2 ◽  
pp. LPI.S848
Author(s):  
José-Luis Pérez-Castrillón ◽  
Manuel Gonzalez-Sagrado ◽  
Marta Gonzalez-Rozas ◽  
Maria Andres-Calvo ◽  
Elena Izquierdo-Delgado ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Acute Coronary Syndrome ◽  
Vascular Disease ◽  
Total Cholesterol ◽  
Bone Mineral ◽  
Ldl Cholesterol ◽  
Hdl Cholesterol ◽  
Mineral Density ◽  
Coronary Syndrome ◽  
The Relationship

Objective To evaluate the relationship between cholesterol and triglycerides and bone mineral density in patients with vascular disease (hypertension and acute coronary syndrome). Methods The study included 217 patients (83 men and 134 women), aged between 36 and 76 (mean age 59 ± 10), with hypertension and acute coronary syndrome. Information obtained included anthropometric measurements, total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides; bone mineral density (BMD) was recorded at the lumbar spine. Results BMD was significantly lower in patients in the higher tertiles of cholesterol (p = 0.041). The effect was maintained after adjustment for age and Body Mass Index (BMI). However, there was no association between the range of triglycerides, LDL cholesterol, HDL cholesterol and bone mass. Conclusions A relationship was found between total cholesterol and bone mineral density in patients with vascular disease.

scholarly journals Bone mineral density, bone remodeling and osteoprotegerin in patients with acute coronary syndrome

2008 ◽  
Vol 129 (1) ◽  
pp. 144-145 ◽  
Author(s):  
Jose Luis Pérez-Castrillon ◽  
Laura Abad ◽  
Gemma Vega ◽  
Alberto Sanz-Cantalapiedra ◽  
Angel San Miguel ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Acute Coronary Syndrome ◽  
Bone Remodeling ◽  
Bone Mineral ◽  
Mineral Density ◽  
Coronary Syndrome

scholarly journals TNF-alpha gene polymorphism and plasma TNF-alpha levels are related to lumbar spine bone area in healthy female Caucasian adolescents

2002 ◽  
pp. 629-634 ◽  
Author(s):  
P Wennberg ◽  
P Nordstrom ◽  
R Lorentzon ◽  
UH Lerner ◽  
M Lorentzon
Keyword(s):  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Femoral Neck ◽  
Bone Mineral ◽  
Adolescent Girls ◽  
Tnf Alpha ◽  
Bone Area ◽  
Mineral Density ◽  
Allelic Variants ◽  
Alpha Gene

OBJECTIVE: The cytokine tumor necrosis factor alpha (TNF-alpha) is an important regulator of bone metabolism. Polymorphisms in the promoter region of the TNF-alpha gene at positions -308 and -863 have been identified. We investigated whether these polymorphisms and circulating TNF-alpha levels were related to bone mineral density and bone area in adolescent girls. DESIGN: Bone mineral density (BMD), bone area (BA), anthropometric characteristics and biochemical analyses were measured in adolescent girls and compared with regard to TNF-alpha genotype. METHODS: Allelic variants of the TNF-alpha gene in 97 girls, aged 16.9+/-1.2 years (mean+/-S.D.), were identified using polymerase chain reaction and the restriction endonucleases NcoI and TaiI. Bone mineral density and bone area of the femoral neck, lumbar spine and total body were measured using dual energy X-ray absorptiometry. RESULTS: Carriers of the rare -863 A allele (n=25) had higher body weight (P=0.03), lumbar spine BMD (P=0.02), and larger total BA (P=0.03), femoral neck area (P<0.05), and lumbar spine area (P=0.01). The independent predictors of BMD and BA were investigated using multiple regression. The TNF-alpha-863 genotypes (beta=0.18, P=0.03) and the TNF-alpha plasma levels (beta=0.19, P=0.04) independently predicted BA of the lumbar spine but not BA or BMD of any other measured sites. No statistically significant differences in body constitution parameters, biochemical parameters, bone density, or bone area at the measured skeletal sites were found when comparing the groups defined by the allelic variants at position -308 (P=0.17-0.84). CONCLUSIONS: We found the TNF-alpha-863 polymorphism and the TNF-alpha plasma levels to be independent predictors of lumbar spine area in healthy Caucasian adolescent females.

scholarly journals Effects of Biological and Non Biological Agents (Disease Modifying Antirheumatic Drugs) on Bone Mineral Density in a Sample of Rheumatoid Arthritis Patients

2018 ◽  
Vol 10 (6) ◽  
pp. 136
Author(s):  
Mohammed Hadi Al-Osami ◽  
Omar Farooq Al-Azzawi ◽  
Faiq Gorial ◽  
Israa Mohammed Redia
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Mineral Density ◽  
Bone Mineral ◽  
Biological Agent ◽  
Tnf Alpha ◽  
Mineral Density ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
High Calcium ◽  
Disease Modifying

BACKGROUND: Osteoporosis is an extra-articular complication of rheuma­toid arthritis that results in increased risk of fractures and associated mor­bidity, mortality, and healthcare costs.OBJECTIVE: To evaluate changes in bone mineral density in a sample of rheumatoid arthritis (RA) patients on biological (anti tumor necrosis factor (TNF) alpha) and non-biological agent disease modifying antirheumatic drugs (DMARDs).PATIENTS &amp; METHODS: A cross sectional study enrolled 60 RA patients diagnosed by rheumatologist according to the 2010 American College of Rheumatology/European League Against Rheumatism (2010 ACR/EULAR) classification criteria for RA. Thirty patient on biological agent (anti TNF alpha) and 30 patient on non-biological agent (DMARD). RA disease-related data wincluded disease duration, disease activity score index of 28 joints (DAS 28) and clinical disease activity index (CDAI), functional class, body mass index and treatment history. vitamin D level were measured in both groups. Bone mineral density was measured by dual energy x-ray absorptiometry of hip and lumber spines for patients. A T –score of equal or less than -2.5 standard deviation that of young healthy adults were taken as osteoporotic and scores between -1 to -2.5 standard deviation was taken as osteopenic.RESULTS: Prevalence of RA patients on biological agent (anti TNF alpha) who had osteoporosis was 1(3%) and 12(40%) were osteopenic, and in patients on non biological (DMARD), Osteoporosis was present in 8(26%) and osteopenia in 13(43%, p= 0.019).Vitamin D level in patient on biological agent (anti TNF alpha) was low in 24(80%) and normal in 6 (20%) patients. While in non biological agent (DMARD) it was low in 13(43.3%) and normal in 17(56.7%) of patients, p=0.003). Patients on biological agent (anti TNF alpha); 15 (50%) patients showed high calcium, 2(6.7%) low phosphorous, and 2(6.7%) high Alkaline phosphatase (ALP) while in patients on non biological agent the results were 10 patients( 33.3%) had high calcium, and 5(16.7%) had high ALP. There was a significant decrease in bone mineral density in RA patients on DMARDS while biological agent (anti TNF alpha) had a role in arrest bone loss in RA patients.CONCLUSIONS: There was a strong association between types of therapy and reduction of bone mineral density.

scholarly journals AB0477 EFFECT OF ANTI-TNF THERAPY ON BONE MINERAL DENSITY IN ANKYLOSING SPONDYLORTHITIS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1266.1-1266
Author(s):  
A. Ajerouassi ◽  
K. Nassar ◽  
S. Janani
Keyword(s):  
Bone Mineral Density ◽  
Femoral Neck ◽  
Bone Mineral ◽  
Spinal Mobility ◽  
Tnf Alpha ◽  
Control Group ◽  
Mineral Density ◽  
T Score ◽  
Significant Difference ◽  
The Mean

Background:Osteoporosis is common in spondyloarthritis, due to reduced spinal mobility, and inflammation. Anti-inflammatory treatments have a beneficial effect on the bone, and there is a significant increase in bone density during treatment with anti-TNF alpha.Objectives:to study bone mineral density in patients with ankylosing spondyloarthritis (AS) treated with anti-TNF alpha.Methods:This is a retrospective descriptive study of patients with AS meeting the modified New York criteria. Bone mineral density, assessed by dual energy x-ray absorptiometry (DXA), of AS patients treated with anti-TNF alpha was compared to that of a control group of AS patients not treated with anti-TNF alpha.Inclusion criteria:- Male patients- Patients who do not have an abnormality disrupting phosphocalcic and bone metabolism- For Patients on anti-TNF alpha: the treatment must be received for more than 6 monthsResults:A total of 22 patients were included, including 11 patients on anti-TNF alpha and 11 patients not on anti-TNF. The mean age (standard deviation) was 28 (± 7.2) years and 41 (± 14.8) in the cases and controls respectively. The mean body mass index in the AS group on anti-TNF was 22.16 kg / m2 and in the control group was 19.64 kg / m2. In the AS group on anti-TNF alpha, the mean bone mineral density of the spine was 1.092 g / cm2 (mean T score = -0.63) and that of the femoral neck, the mean bone mineral density was 0.888g / cm2 (mean T score = -1.04). In the control group, the mean bone mineral density of the spine was 0.959 g / cm2 (mean T score = -1.91) and the mean bone mineral density of the femoral neck was 0.774 g / cm2 (mean T score = -1.99). Bone mineral density in the spine and cervix was higher in the group receiving anti-TNF alpha (p = 0.09, p = 0.173 respectively)Conclusion:Our study shows the increase, although not statistically significant, in bone mineral density in AS patients receiving anti-TNF alpha agents compared to controls. Our results agree with those of the literature which support the bone protective effect of anti-TNF alpha. The non-significant difference can be explained by the delay in the introduction of biotherapy at the advanced stage of the structural evolution of AS. The best solution is to start TNF inhibitors at the early inflammatory stage of AS.Disclosure of Interests:None declared.

scholarly journals Long‐Term Treatment With TNF‐Alpha Inhibitors Improves Bone Mineral Density But Not Vertebral Fracture Progression in Ankylosing Spondylitis

2019 ◽  
Vol 34 (6) ◽  
pp. 1041-1048 ◽  
Author(s):  
Kimberley Johanna Beek ◽  
Tamara Rusman ◽  
Maria Alida Cornelia van der Weijden ◽  
Willem Frederik Lems ◽  
Johannes Christiaan van Denderen ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Ankylosing Spondylitis ◽  
Vertebral Fracture ◽  
Bone Mineral ◽  
Term Treatment ◽  
Tnf Alpha ◽  
Mineral Density ◽  
Long Term Treatment
Sign in / Sign up

Export Citation Format

Share Document